These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38489183)

  • 1. Alzheimer's Disease Immunotherapy: Current Strategies and Future Prospects.
    Aljassabi A; Zieneldien T; Kim J; Regmi D; Cao C
    J Alzheimers Dis; 2024; 98(3):755-772. PubMed ID: 38489183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
    Cribbs DH
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-β-targeting immunotherapies for Alzheimer's disease.
    Jin Y; Du Q; Song M; Kang R; Zhou J; Zhang H; Ding Y
    J Control Release; 2024 Nov; 375():346-365. PubMed ID: 39271059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
    Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
    Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
    Herline K; Drummond E; Wisniewski T
    Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive immunotherapy for Alzheimer's disease.
    Guo X; Yan L; Zhang D; Zhao Y
    Ageing Res Rev; 2024 Feb; 94():102192. PubMed ID: 38219962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.
    Song C; Shi J; Zhang P; Zhang Y; Xu J; Zhao L; Zhang R; Wang H; Chen H
    Transl Neurodegener; 2022 Mar; 11(1):18. PubMed ID: 35300725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
    Tarawneh R; Holtzman DM
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.
    Vander Zanden CM; Chi EY
    J Pharm Sci; 2020 Jan; 109(1):68-73. PubMed ID: 31647950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice.
    Liu S; Shi D; Wang HC; Yu YZ; Xu Q; Sun ZW
    Sci Rep; 2015 Jan; 5():7771. PubMed ID: 25586780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Trends in Active and Passive Immunotherapies of Alzheimer's Disease.
    Alshamrani M
    Antibodies (Basel); 2023 Jun; 12(2):. PubMed ID: 37366656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Alzheimer's disease.
    Wisniewski T; Goñi F
    Biochem Pharmacol; 2014 Apr; 88(4):499-507. PubMed ID: 24412277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
    Gnoth K; Piechotta A; Kleinschmidt M; Konrath S; Schenk M; Taudte N; Ramsbeck D; Rieckmann V; Geissler S; Eichentopf R; Barendrecht S; Hartlage-Rübsamen M; Demuth HU; Roßner S; Cynis H; Rahfeld JU; Schilling S
    Alzheimers Res Ther; 2020 Nov; 12(1):149. PubMed ID: 33189132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
    Behl T; Kaur I; Fratila O; Brata R; Bungau S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
    Nitsch RM; Hock C
    Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.